Article Text

PDF
THU0184 Identification of biomarkers in SLE pregnancies using urinary proteomics
  1. K. Schreiber1,
  2. K. Bramham2,
  3. H. Mistry2,
  4. O. Barrutia-Ateka1,
  5. S. Lynham3,
  6. A. Weston3,
  7. M.A. Ward3,
  8. L.M. Bertolaccini1,
  9. L.C. Chappell2,
  10. M.A. Khamashta1
  1. 1Lupus Unit
  2. 2Maternal and Fetal Research Unit, Devision of Women’s Health
  3. 3Proteomics Centre, Institute of Psychiatry, King’s College London, London, United Kingdom

Abstract

Background Pre-eclampsia affects 2-7% of all pregnancies (1), is a leading cause of maternal morbidity and mortality and increases perinatal mortality five-fold (2). Women with Systemic Lupus Erythematosus (SLE) have a particularly high risk of developing pre-eclampsia (3) and patients with specific organ involvement (i.e. lupus nephritis) are at higher risk of developing pre-eclampsia earlier in their pregnancy (4).

Objectives This study aims to identify human pregnancy biomarkers in the urinary proteome to improve the diagnosis and/or prediction of pre-eclampsia in patients with SLE.

Methods Second trimester urine samples were collected from 3 women with SLE and lupus nephritis who subsequently developed pre-eclampsia, 5 SLE gestation-matched patients who did not develop pre-eclampsia and 6 healthy controls. Samples were prepared following our optimized workflow using in-gel trypsin digestion followed by LC-MS/MS. Spectral abundance of differentially expressed proteins was analysed using minimal stringency settings in Scaffold software.

Results Our preliminary data suggest that pre-eclampsia results in a distinctive urinary proteome in women with lupus nephritis, but also in controls compared to women without pre-eclampsia (Figure 1a and b). One hundred and sixteen proteins were identified; of these, 6 proteins were found to be present only in the SLE pre-eclampsia urine samples (arrow). Furthermore, two proteins were found to be present in SLE pre-eclampsia (arrow), but showed a difference in SLE non-pre-eclampsia urinary samples and were absent in the samples from women with SLE without pre-eclampsia (circled in black) (Figure 1b).

Conclusions Previous work in this group involving pre-eclamptic samples has used targeted mass spectrometry for relative quantitation in a validation sample set. Our study shows differentially expressed proteins, representing potential biomarker candidates of pre-eclampsia in patients with SLE/APS and hence warrant further investigation.

  1. Sibai B et al., Lancet 2005;365:785-99.

  2. Roberts J.M.; Placenta 2002;23:359-72.

  3. Salmon JE et al., PLoS Med. 2011;8:e1001013.

  4. Bramham K et al., J Rheumatol 2011 Jun 1.

Disclosure of Interest K. Schreiber Grant/Research support from: ESF - Biolupus, K. Bramham: None Declared, H. Mistry: None Declared, O. Barrutia-Ateka: None Declared, S. Lynham: None Declared, A. Weston: None Declared, M. Ward: None Declared, L. M. Bertolaccini: None Declared, L. C. Chappell: None Declared, M. Khamashta: None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.